TY - JOUR
T1 - Beta adrenergic-mediated myofibrillar disruption and enzyme efflux in an experimental myopathy related to isometric muscle activity
AU - Kuncl, Ralph W.
AU - Meltzer, Herbert Y.
PY - 1979/8
Y1 - 1979/8
N2 - Adrenal demedullation significantly inhibits the enormous increase in plasma creatine phosphokinase (CPK) activity and myofibrillar disruption which follow treatment with phencyclidine (PCP) and restraint in the rat. To determine if the effects of adrenal demedullation were due to the lack of epinephrine, we studied the effects of the β-adrenergic receptor blockers, propranolol and 3-morpholino-4-[3-t-butyl-amino-2-hydroxypropoxy]-1,2,5-thiadiazole hydrogen maleate (MK-950) on these myopathic parameters in intact rats subjected to PCP plus restraint. Both drugs significantly inhibited the myopathy. Pretreatment with either phenoxybenzamine, at effective α-adrenergic receptor blocking doses, or atropine, at effective antimuscarinic anticholinergic doses, had no effect on these parameters. Plasma CPK activity and the percentage of muscle fibers with extensive myofibrillar disruptions following PCP and restraint were significantly correlated for all treatments, except phenoxybenzamine (r = +0.71, N = 17, P < 0.001). These findings indicate the importance of adrenal epinephrine to the etiology of this myopathy. It is proposed that epinephrine stimulates a β-adrenergic process which ultimately leads to a hypoxic state and muscle injury.
AB - Adrenal demedullation significantly inhibits the enormous increase in plasma creatine phosphokinase (CPK) activity and myofibrillar disruption which follow treatment with phencyclidine (PCP) and restraint in the rat. To determine if the effects of adrenal demedullation were due to the lack of epinephrine, we studied the effects of the β-adrenergic receptor blockers, propranolol and 3-morpholino-4-[3-t-butyl-amino-2-hydroxypropoxy]-1,2,5-thiadiazole hydrogen maleate (MK-950) on these myopathic parameters in intact rats subjected to PCP plus restraint. Both drugs significantly inhibited the myopathy. Pretreatment with either phenoxybenzamine, at effective α-adrenergic receptor blocking doses, or atropine, at effective antimuscarinic anticholinergic doses, had no effect on these parameters. Plasma CPK activity and the percentage of muscle fibers with extensive myofibrillar disruptions following PCP and restraint were significantly correlated for all treatments, except phenoxybenzamine (r = +0.71, N = 17, P < 0.001). These findings indicate the importance of adrenal epinephrine to the etiology of this myopathy. It is proposed that epinephrine stimulates a β-adrenergic process which ultimately leads to a hypoxic state and muscle injury.
UR - http://www.scopus.com/inward/record.url?scp=0018735991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018735991&partnerID=8YFLogxK
U2 - 10.1016/0014-4800(79)90012-1
DO - 10.1016/0014-4800(79)90012-1
M3 - Article
C2 - 37103
AN - SCOPUS:0018735991
SN - 0014-4800
VL - 31
SP - 113
EP - 123
JO - Experimental and Molecular Pathology
JF - Experimental and Molecular Pathology
IS - 1
ER -